Identification of kinase inhibitors

• US 7,202,033 B2
• Filed: 03/20/2003
• Issued: 04/10/2007
• Est. Priority Date: 03/21/2002
• Status: Expired due to Fees

• Current Assignee: Sunesis Pharmaceuticals, Inc. (Viracta Therapeutics, Inc.)
• Original Assignee: Sunesis Pharmaceuticals, Inc. (Viracta Therapeutics, Inc.)
• Inventors: Braisted, Andrew, Prescott, John C.
• Primary Examiner(s): Shibuya; Mark L.
• Assistant Examiner(s): Lundgren; Jeffrey S.
• Application Number:
  US10/394,322
• Publication Number:
  US 20030232391A1
• Time in Patent Office: 1,482 Days
• Field of Search: None
• US Class Current: 435/6.14
• CPC Class Codes: C12Q 1/485 involving kinase
• CPC Class Codes: C40B 30/04 by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
• CPC Class Codes: G01N 2500/00 Screening for compounds of potential therapeutic value

Abstract

The invention concerns the identification of protein kinase inhibitors that preferentially bind to the inactive conformation of a target protein kinase. The inhibitors are identified by locking the target protein kinase in an inactive conformation, and using a covalent tethering approach to identify inhibitors preferentially targeting the inactive conformation.

Claims

1. A method for identifying ligands binding to an inactive conformation of a target protein kinase, comprising

(a) contacting the inactive conformation of said protein kinase having a first and a second binding site of interest and containing or modified to contain a nucleophile at or near the first site of interest with a plurality of ligand candidates, said candidates having a functional group reactive with the nucleophile, under conditions such that a reversible covalent bond is formed between the nucleophile and a candidate that has affinity for the first site of interest, to form a kinase-first ligand complex;

(b) identifying the first ligand from the complex of (a);

(c) designing a derivative of the first ligand identified in (a) to provide a small molecule extender (SME) having a first functional group reactive with the nucleophile on the kinase and a second functional group reactive with a second ligand having affinity for the second binding site of interest;

(d) contacting the SME with the kinase to form a kinase-SME complex, and

(e) contacting the kinase-SME complex with a plurality of second ligand candidates, said candidates having a functional group reactive with the SME in said kinase-SME complex, wherein a candidate that has affinity for said second binding site of interest on said kinase forms a reversible covalent bond with said kinase-SME complex, whereby a second ligand is identified.

2. The method of claim 1 wherein said nucleophile is selected from the group consisting of —

SH, —

OH, —

NH₂ and —

COOH groups.

3. The method of claim 2 wherein said nucleophile is provided by a side chain of an amino acid residue selected from the group consisting of cysteine, serine, threonine, lysine, asparagine, and glutamine.

4. The method of claim 3 wherein said nucleophile is an —

SH group provided by the side chain of a cysteine residue.

5. The method of claim 4 wherein said kinase contains said cysteine residue without further modification.

6. The method of claim 5 wherein said cysteine residue is selected from the group consisting of C53 of CDK5;

C183 of ERK1;

C166 of ERK2;

C28 of ERK3;

C488 of FGFR1;

C491 of FGFR2;

C482 of FGFR3;

C477 of FGFR4;

C533 of NIK;

C835 of PDGFR-a;

C-843 of PDGFR-b;

C279 of SRC;

C273 of SRC2;

C828 of STK1;

C39 of TGFR2;

C1039 of VEGFR1;

C1045 of VEGFR2;

C1054 of VEGFR3;

C287 of YES; and

C346 of ZAP-70.

7. The method of claim 4 wherein said kinase is modified to contain said cysteine residue.

8. The method of claim 7 wherein said cysteine residue is introduced into said target protein kinase to result in a variant selected from the group consisting of E234C AKT1;

E236C ALT2;

E232C AKT3;

D86C CDK1;

D86C CDK2;

D86C CDK3;

D99C CDK4;

D86C CDK5;

D104C CDK6;

D97C CDK7;

D103C CDK8;

D108C CDK9;

S273C CSK;

D128C ERK1;

D111C ERK2;

D114C ERK3;

D111C ERK4;

D142C ERK5;

D115C ERK6;

E506C FAK1;

N568C FGFR1;

N571C FGFR2;

N562C FGFR3;

N557C FGFR4;

D348C FYN;

S340C HCK;

D102C IKK-a;

D103C IKK-b;

S93C IKK-e;

S951C JAK1;

S936C JAK2;

N114C JNK1;

N114C JNK2;

N152C JNK3;

S322C LCK;

S325C LYN;

D112C MAPK;

S476C NIK;

S351C PAK1;

S330C PAK2;

S349C PAK3;

A402C PAK4;

A530C PAK5;

D861C PDGFR-a;

D688C PDGFR-b;

D128C PIM1;

S389C A-Raf;

S535C B-Raf;

S428C C-Raf;

S347C SRC;

S341C SRC2;

D698C STK1;

P455C SYK;

S287C TGFR1;

N332C TGFR2;

N924C TIE1;

N909C TIE2;

N917C VEGFR1;

N923C VEGFR2;

N934C VEGFR3;

S355C YES; and

P421C ZAP-70.

9. The method of claim 4 wherein said SME comprises a group capable of undergoing SN2-like attack or forming a Michael-type adduct with the —

SH group of said cysteine residue.

10. The method of claim 9 wherein said group is selected from the group consisting of α

-halo acids, fluorophoph(on)ates, epoxides, aziridines, thiiranes, halo-methyl ketones, and halo-methyl amides.

11. The method of claim 4 wherein said second functional group is an —

SH group.

12. The method of claim 1 wherein wherein said ligand candidates are members of a small molecule library of less than 1500 daltons, less than 1000 daltons, less than 750 daltons, less than 500 daltons, or less than 250 daltons in size.

13. The method of claim 12 wherein each member of said library differs in molecular weight from each other member of said library.

14. The method of claim 13 wherein said library contains 1 to 100 members.

15. The method of claim 1 wherein said small molecule extender is selected from the group consisting of

16. The method of claim 15 wherein R¹ is a Michael acceptor selected from the group consisting of

17. The method of claim 15, wherein R3 is a Michael acceptor selected from the group consisting of

18. A method for identifying ligands binding to an inactive conformation of a target protein kinase, comprising

(a) screening a library of ligand candidates with a kinase-ligand conjugate formed by the covalent bonding of the inactive conformation of a kinase comprising a first reactive functionality with a compound that comprises (1) a second reactive functionality and (2) a chemically reactive group, wherein the second reactive functionality of the compound reacts with the first reactive functionality of the inactive conformation of said target protein kinase to form a first covalent bond such that the kinase-ligand conjugate contains a free chemically reactive group, under conditions wherein at least one member of the library forms a second covalent bond with the kinase-ligand conjugate;

and

(b) identifying a further ligand that binds covalently to the chemically reactive group of the kinase-ligand conjugate.

19. The method of claim 18 wherein the first reactive functionality of the kinase comprises a nucleophile that is selected from the group consisting of —

SH, —

OH, —

NH₂ and —

COOH groups.

20. The method of claim 19 wherein said nucleophile is provided by a side chain of an amino acid residue selected from the group consisting of cysteine, serine, threonine, lysine, asparagine, and glutamine.

21. The method of claim 18 wherein said nucleophile is an —

SH group provided by the side chain of a cysteine residue.

22. The method of claim 21 wherein said cysteine residue is selected from the group consisting of C53 of CDK5;

C183 of ERK1;

C166 of ERK2;

C28 of ERK3;

C488 of FGFR1;

C491 of FGFR2;

C482 of FGFR3;

C477 of FGFR4;

C533 of NIK;

C835 of PDGFR-a;

C-843 of PDGFR-b;

C279 of SRC;

C273 of SRC2;

C828 of STK1;

C39 of TGFR2;

C1039 of VEGFR1;

C1045 of VEGFR2;

C1054 of VEGFR3;

C287 of YES; and

C346 of ZAP-70.

23. The method of claim 21 wherein said kinase is modified to contain said cysteine residue.

24. The method of claim 23 wherein said cysteine residue is introduced into said target protein kinase to result in a variant selected from the group consisting of E234C AKT1;

E236C ALT2;

E232C AKT3;

D86C CDK1;

D86C CDK2;

D86C CDK3;

D99C CDK4;

D86C CDK5;

D104C CDK6;

D97C CDK7;

D103C CDK8;

D108C CDK9;

S273C CSK;

D128C ERK1;

D111C ERK2;

D114C ERK3;

D111C ERK4;

D142C ERK5;

D115C ERK6;

E506C FAK1;

N568C FGFR1;

N571C FGFR2;

N562C FGFR3;

N557C FGFR4;

D348C FYN;

S340C HCK;

D102C IKK-a;

D103C IKK-b;

S93C IKK-e;

S951C JAK1;

S936C JAK2;

N114C JNK1;

N114C JNK2;

N152C JNK3;

S322C LCK;

S325C LYN;

D112C MAPK;

S476C NIK;

S351C PAK1;

S330C PAK2;

S349C PAK3;

A402C PAK4;

A530C PAK5;

D861C PDGFR-a;

D688C PDGFR-b;

D128C PIM1;

S389C A-Raf;

S535C B-Raf;

S428C C-Raf;

S347C SRC;

S341C SRC2;

D698C STK1;

P455C SYK;

S287C TGFR1;

N332C TGFR2;

N924C TIE1;

N909C TIE2;

N917C VEGFR1;

N923C VEGFR2;

N934C VEGFR3;

S355C YES; and

P421C ZAP-70.

25. The method of claim 21 wherein said kinase-ligand conjugate is formed from the ligand comprising a group capable of undergoing SN2-like attack or forming a Michael-type adduct with the —

SH group of said cysteine residue.

26. The method of claim 25 wherein said group capable of undergoing SN2-like attack is selected from the group consisting of α

-halo acids, fluorophosph(on)ates, epoxides, aziridines, thiiranes, halo-methyl ketones, and halo-methyl amides.

27. The method of claim 21 wherein said free chemically reactive group is an —

SH group.

28. The method of claim 18 wherein wherein said ligand candidates are members of a small molecule library of less than 1500 daltons, less than 1000 daltons, less than 750 daltons, less than 500 daltons, or less than 250 daltons in size.

29. The method of claim 28 wherein each member of said library differs in molecular weight from each other member of said library.

30. The method of claim 29 wherein said library contains 1 to 100 members.